Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study

被引：0
|
作者：
E Van Cutsem
C-P Li
E Nowara
G Aprile
M Moore
I Federowicz
J-L Van Laethem
C Hsu
C K Tham
S M Stemmer
R Lipp
A Zeaiter
A Fittipaldo
Z Csutor
B Klughammer
X Meng
T Ciuleanu
机构：
[1] Gastroenterology/Digestive Oncology,Division of Gastroenterology, Department of Medicine
[2] University Hospitals Leuven and KU Leuven,Department of Medical Oncology
[3] Taipei Veterans General Hospital,Division of Medical Oncology and Hematology
[4] National Yang-Ming University School of Medicine,Department of Gastroenterology
[5] Centrum Onkologii—Instytut im. Marii Skłodowskiej-Curie Oddział w Gliwicach,GI Cancer Unit
[6] ul. Wybrzeże Armii Krajowej 15,Department of Medical Oncology
[7] University Hospital of Udine,undefined
[8] Princess Margaret Hospital,undefined
[9] NZOZ Magodent,undefined
[10] Erasme University Hospital-ULB-Brussels,undefined
[11] National Taiwan University Hospital,undefined
[12] National Cancer Center Singapore,undefined
[13] Institute of Oncology,undefined
[14] Davidoff Center,undefined
[15] Rabin Medical Center,undefined
[16] GermanOncology GmbH,undefined
[17] Roche Products Ltd,undefined
[18] F. Hoffmann-La Roche,undefined
[19] PD Biostatistics,undefined
[20] Roche,undefined
[21] Institute of Oncology Ion Chiricuta and UMF Iuliu Hatieganu,undefined
来源：
British Journal of Cancer | 2014年 / 111卷
关键词：
pancreatic cancer; erlotinib; epidermal growth factor; oncology; dose; rash;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2067 / 2075
页数：8
相关论文
共 50 条
  • [21] Phase I randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib as first-line treatment in patients with metastatic pancreatic cancer (SWOG-0727).
    Philip, Philip Agop
    Goldman, Bryan H.
    Ramanathan, Ramesh K.
    Lenz, Heinz-Josef
    Lowy, Andrew M.
    Whitehead, Robert P.
    Iqbal, Syma
    Gaur, Rakesh
    Benedetti, Jacqueline K.
    Blanke, C. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [22] Phase II study of gemcitabine plus cisplatin in metastatic breast cancer
    Fuentes, Homero
    Calderillo, German
    Alexander, Francisco
    Ramirez, Marcelino
    Avila, Enrique
    Perez, Leonel
    Aguirre, Guillermo
    Onate-Ocana, Luis F.
    Gallardo, Dolores
    Otero, Jorge
    ANTI-CANCER DRUGS, 2006, 17 (05) : 565 - 570
  • [23] Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer
    Van Cutsem, Eric
    Hidalgo, Manuel
    Canon, Jean-Luc
    Macarulla, Teresa
    Bazin, Igor
    Poddubskaya, Elena
    Manojlovic, Nebojsa
    Radenkovic, Dejan
    Verslype, Chris
    Raymond, Eric
    Cubillo, Antonio
    Schueler, Armin
    Zhao, Charles
    Hammel, Pascal
    INTERNATIONAL JOURNAL OF CANCER, 2018, 143 (08) : 2053 - 2064
  • [24] Cost-effectiveness of nab-paclitaxel plus gemcitabine versus erlotinib plus gemcitabine in metastatic pancreatic cancer
    Chiorean, E. Gabriela
    Whiting, Scott
    Binder, Gary
    Dranitsaris, George
    Manax, Victoria
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [25] Phase II Study of Gemcitabine and Erlotinib as Adjuvant Therapy for Patients with Resected Pancreatic Cancer
    Philip Q. Bao
    Ramesh K. Ramanathan
    Alyssa Krasinkas
    Nathan Bahary
    Barry C. Lembersky
    David L. Bartlett
    Steven J. Hughes
    Kenneth K. Lee
    A. James Moser
    Herbert J. Zeh
    Annals of Surgical Oncology, 2011, 18 : 1122 - 1129
  • [26] Phase II Study of Gemcitabine and Erlotinib as Adjuvant Therapy for Patients with Resected Pancreatic Cancer
    Bao, Philip Q.
    Ramanathan, Ramesh K.
    Krasinkas, Alyssa
    Bahary, Nathan
    Lembersky, Barry C.
    Bartlett, David L.
    Hughes, Steven J.
    Lee, Kenneth K.
    Moser, A. James
    Zeh, Herbert J., III
    ANNALS OF SURGICAL ONCOLOGY, 2011, 18 (04) : 1122 - 1129
  • [27] A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer
    Oh, D.
    Lee, K.
    Lee, K.
    Sohn, C.
    Zang, D.
    Ryoo, H.
    Song, H.
    Kim, J.
    Bang, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [28] Rash as a marker for the efficacy of gemcitabine plus erlotinib-based therapy in pancreatic cancer: Results from the AViTA Study
    Verslype, C.
    Vervenne, W.
    Bennouna, J.
    Humblet, Y.
    Cosaert, J.
    Van Cutsem, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [29] Dose Finding and Early Efficacy Study of Gemcitabine Plus Capecitabine in Combination With Bevacizumab Plus Erlotinib in Advanced Pancreatic Cancer
    Starling, Naureen
    Watkins, David
    Cunningham, David
    Thomas, Janet
    Webb, Janine
    Brown, Gina
    Thomas, Karen
    Oates, Jacqui
    Chau, Ian
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (33) : 5499 - 5505
  • [30] A phase II study of capecitabine plus docetaxel in gemcitabine-pretreated metastatic pancreatic cancer patients: CapTere
    Soares, Heloisa P.
    Bayraktar, Soley
    Blaya, Marcelo
    Lopes, Gilberto
    Merchan, Jaime
    Macintyre, Jessica
    Mayo, Carlos
    Green, Mark R.
    Silva, Orlando
    Levi, Joe
    Walker, Gail
    Rocha-Lima, Caio M.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (04) : 839 - 845
12345